Goldman says the M&A boom has room to run, flags new takeover candidates
Goldman Sachs says the U.S. M&A boom has further room to run, citing about $1.2 trillion in announced deals this year, up 32% from the same period in 2025, and a 12% rise in deal count, per Goldman. It refreshed a basket of 71 stocks on July 1, noting valuations of likely targets may not fully reflect takeover odds. Candidates include IMAX, ConocoPhillips, Freeport-McMoRan, Diamondback Energy, Occidental, SBA Communications, Nutanix and Dynatrace.
How this was made
The 30-second read
Why it matters
The actionable content is analyst-driven takeover-candidate ranking across multiple sectors, supported by deal-count and value growth statistics and recent basket outperformance.
Market read
Traders may use the basket as a short-term screen for M&A sentiment, but the article does not disclose any new bids, filings, or deal terms.
What to watch
Regulatory or financing conditions could tighten quickly, and the article itself warns deterioration in investor sentiment could derail acquisitions.
Background
Goldman argues the M&A surge is not fully priced into likely targets’ valuations and points to a refreshed basket of 71 stocks with at least a 15% acquisition probability over 12 months.
Ticker impact
Goldman flags Imax as a highest-ranked takeover candidate outside biotechnology, implying potential M&A upside not fully priced in valuations.
Mild, sentiment-driven outperformance versus peers is possible, but follow-through depends on real deal headlines.
The only company-specific content is Goldman’s refreshed basket ranking and valuation-probability argument, not a disclosed transaction.
ConocoPhillips is listed by Goldman among top takeover candidates outside biotechnology, tied to the view that target valuations lag acquisition odds.
Short-term relative strength is plausible if the market trades Goldman’s basket, but magnitude is uncertain.
No new corporate action is reported; the catalyst is analyst positioning and probability framing.
Freeport-McMoRan is highlighted as a top takeover candidate outside biotechnology in Goldman’s refreshed 71-stock acquisition-probability basket.
Limited upside bias versus the index if investors chase M&A narratives.
The article cites outperformance of the basket and valuation logic, not a specific offer or negotiation.
Diamondback Energy appears among Goldman’s highest-ranked takeover candidates outside biotechnology, with the thesis that valuations do not reflect above-average buyout odds.
Gradual, narrative-driven support rather than a discrete repricing event.
The text is an analyst note summary; no new bid, process, or regulatory event is disclosed.
Occidental Petroleum is named by Goldman as a top takeover candidate outside biotechnology, tied to the view that the merger cycle is not fully priced.
Possible short-term relative outperformance if the market trades the basket.
Company-specific information is limited to ranking and the general M&A valuation argument.
SBA Communications is included among Goldman’s highest-ranked takeover candidates outside biotechnology, suggesting acquisition probability remains underpriced.
Moderate narrative support; sustained impact requires subsequent deal headlines.
No new corporate event is reported beyond Goldman’s refreshed basket and sector broadening.
Goldman highlights software company Nutanix as a takeover candidate, reinforcing its thesis that target valuations lag the probability of being bought.
Speculative upside bias, likely capped without concrete deal developments.
The only actionable element is inclusion in a ranked basket and the general M&A-cycle argument.
Dynatrace is called out by Goldman as a highlighted software takeover candidate within its 71-stock acquisition-probability basket.
Small-to-moderate relative strength possible, but not a high-conviction repricing.
The article provides no new bid, negotiations, or filings; it is an analyst note summary.
Market effects
Reinforces read-through that healthcare and then technology/media/telecom targets are starting to outperform, consistent with a broadening M&A bid narrative.
Primarily US-focused deal statistics and US takeover-candidate framing.
Limited direct global impact; the thesis is about US merger-cycle pricing and target valuation gaps.
Counterpoint
Valuation underpricing claims may not translate into actual bids; a basket outperformance can reflect momentum and sector rotation rather than imminent takeovers.
Key entities
- financial_institutionGoldman Sachs
Provides the note’s thesis on the merger cycle and a refreshed basket of takeover candidates.
- companyImax
Named among highest-ranked takeover candidates outside biotechnology.
- companyConocoPhillips
Named among highest-ranked takeover candidates outside biotechnology.
- companyFreeport-McMoRan
Named among highest-ranked takeover candidates outside biotechnology.
- companyDiamondback Energy
Named among highest-ranked takeover candidates outside biotechnology.
